PBAC's latest decision on Nicotine: Recommended (2018). Considered for Nicotine dependence in cigarette smokers who wish to quit and enter into a behavioural support program. Available as gum (2 mg, 4 mg) and lozenge (2 mg, 4 mg) formulations.
PBAC outcome
Recommended
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
2
first 2017
Submissions
2
2017 → 2018
Eligible population
Cigarette smokers with nicotine dependence (high or moderate) who wish to quit and are entering or undergoing a comprehensive behavioural support and counselling program
Therapy area
Addiction medicine
Line of therapy
Not applicable
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
nicotine patches
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated. Gum and lozenges were priced to be cost-neutral against nicotine patches.
Submission history
Jul 2017: Recommended with restriction · Restricted